Genetic Analysis AS, a science-based diagnostic company, develops diagnostic solutions for human microbiome market in the United States, Europe, and internationally. It offers GA-map, a platform for the analysis of the human gut microbiota; GA-map Dysbiosis Test that detects and characterizes dysbiosis; and GA-map Analyzer, a cloud-based software solution. The company also provides GA-map Discovery, a tool to search biomarkers and validate research findings or transfer the findings to a ready-to-use routine testing platform; GA-map Sample Collection Kit used for collection, transport, and storage of fecal specimens for nucleic acid analyses; and GA-map Covid-19 Fecal Test, a non-invasive test with an easy-to-use home sampling procedure. Further, it offers laboratory services; and bioinformatic analysis services. The company develops rapid microbiome-based PCR test. Genetic Analysis AS was founded in 2008 and is headquartered in Oslo, Norway.
Q4 2025 is off to a flying start with record highs being printed left, right, and center. US and Japanese stocks made fresh new highs, while the gold price powered through $4,000 for the first time, and Bitcoin crossed the $126k level. Is this all a case of USD weakness, irrational exuberance, or solid fundamentals? This week, we are reviewing Q3 market performance, Q2 earnings season, and the outlook heading into the end of 2025…
The market has been flat in the last week, however the Industrials sector is down 3.6%. As for the longer term, the market has risen 7.4% in the past 12 months. Looking forward, earnings are forecast to grow by 14% annually. Market details ›